【摘要】 目的了解鲍曼不动杆菌(A.ba)的耐药性及流行情况,为A.ba感染的治疗与预防提供参考。方法采用WHONET 5.6软件对临床分离的1 486株A.ba的耐药性及耐药谱进行分析。结果 A.ba对头孢类、喹诺酮类、氨基糖苷类及碳青霉烯类药物的耐药率均超过75%;但对头孢哌酮/舒巴坦及米诺环素较为敏感,耐药率为24.5%和23.8%;A.ba对左旋氧氟沙星等11种抗菌素泛耐药的检出率高达20.8%,且泛耐药菌株的检出率在ICU病房与普通内科病房之间差异不明显,而敏感菌株的检出率ICU病房明显低于内科病房。结论泛耐药A.ba的增多与抗生素的过度使用有关,对A.ba感染的治疗可首选舒巴坦酶抑制剂的复合药物或米诺环素。更多还原

【Abstract】 Objective To investigate the drug resistance and epidemiology features of Acinetobacter baumannii,so as to provide references for clinical treatment and prevention of Acinetobacter baumanni infection. Methods The WHONET5. 6 software was used to analyze the drug resistance of 1486 Acinetobacter baumanni isolates from inpatients of the hospital. Results The drug resistance rates of Acinetobacter baumanni to cephalosporins,quinolone,aminoglycoside and carbapenems were all above 75%. However,Acinetobacter baumanni was more sensitive to Cefoperazone / sulbactam and minocycline,and the resistance rates were 24. 5% and 23. 8% respectively. The isolation rate of pan-drug resistant Acinetobacter baumanni( PDRAB) which were resistant to levofloxacin and other 11 antibiotics was 20. 8%. Furthermore,there was no significant difference in PDRAB isolation rates between ICU and internal medicine ward,but the detection rate of the sensitive strains in ICU was significantly lower than that in internal medicine ward. Conclusion The increase of PDRAB was related to the overuse of antibiotics. Sulbactam inhibitor compound drugs and minocycline were recommended to be the first choice of the treatment of Acinetobacter baumanni infection.更多还原